Lynparza (olaparib) has demonstrated another benefit for patients with a specific genetic mutation – this time in a Phase 3 trial of men with metastatic castration-resistant prostate cancer. Lynparza is a poly ADP ribose polymerase (PARP) inhibitor that is already approved for ovarian, breast and pancreatic cancers.
